Physician profile
Robert Simon
NPI 1740577022
$6,844.65
in general payments reported to CMS, 2019-2025
22 companies · $1,620 in 2025
The $1,620 reported for 2025 was more than what 79% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $808 · 2020: $13.57 · 2021: $391 · 2022: $673 · 2023: $942 · 2024: $2,396 · 2025: $1,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,740 · Travel and Lodging: $210 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,739.69 |
| Travel and Lodging | $209.96 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,524.17 | 2019-2025 | Da Vinci Surgical System |
| Boston Scientific Corporation | $1,256.53 | 2021-2025 | Spyglass Discover, Spyglass |
| Dilon Technologies, INC. | $866.69 | 2023-2025 | Hemoblast Bellows |
| Medtronic, INC. | $787.08 | 2022-2025 | Signia, Ligasure, Prodigi |
| W. L. Gore & Associates, INC. | $349.26 | 2019-2023 | Gore Synecor Biomaterial |
| Teleflex LLC | $227.78 | 2022 | |
| Aroa Biosurgery Incorporated | $219.83 | 2024 | |
| Ethicon US, LLC | $165.71 | 2019-2025 | Echelon; Endopath |
| Solventum Corporation | $147.29 | 2024 | Prevena, Abthera Advance, V.A.C.Instill |
| Davol INC. | $143.35 | 2024 | Phasix Mesh |
| Baxter Healthcare | $136.00 | 2025 | Floseal |
| Novartis Pharmaceuticals Corporation | $130.27 | 2019-2020 | |
| Madrigal Pharmaceuticals | $124.93 | 2025 | Rezdiffra |
| Myriad Genetic Laboratories, INC. | $124.85 | 2025 | Myrisk |
| Haemonetics Corporation | $124.04 | 2025 | Teg6s Hemostasis System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $119.74 | 2025 | |
| Angiodynamics, INC. | $117.00 | 2025 | Nanoknife |
| Abbvie INC. | $86.98 | 2023 | |
| Integra Lifesciences Corporation | $82.26 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Vivus LLC | $71.22 | 2023 | Qsymia |
| Merck Sharp & Dohme LLC | $23.11 | 2024 | Dificid |
| Covidien Lp | $16.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.